$0.1400
At close: Apr 3, 9:33 AM EDT
Comments
Loading...
InnoCan Pharma Analyst Ratings and Price Targets | OTC:INNPF | Benzinga
InnoCan Pharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for InnoCan Pharma Corp from these most-recent analyst ratings.
Analyst Ratings for InnoCan Pharma
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for InnoCan Pharma (INNPF) stock?
There is no price target for InnoCan Pharma
What is the most recent analyst rating for InnoCan Pharma (INNPF)?
There is no analyst for InnoCan Pharma
When was the last upgrade for InnoCan Pharma (INNPF)?
There is no last upgrade for InnoCan Pharma
When was the last downgrade for InnoCan Pharma (INNPF)?
There is no last downgrade for InnoCan Pharma.
When is the next analyst rating going to be posted or updated for InnoCan Pharma (INNPF)?
There is no next analyst rating for InnoCan Pharma.
Is the Analyst Rating InnoCan Pharma (INNPF) correct?
There is no next analyst rating for InnoCan Pharma.
Browse analyst ratings and price targets on all stocks.